But Novo Nordisk, the Danish pharma big behind the ‘miracle’ drug, has already admitted that only a ‘proportion’ of already restricted inventory will be shared with the health service, with the rest allocated to personal firms. Experts hit out at the move, arguing that ‘would not make sense’ and will depart these most in need with out access to Wegovy. About a hundred and eighty,000 Brits with kind 2 diabetes are set to be given tirzepatide to help management their condition, trials have additionally proven individuals taking the jab can lose up to 20 per cent of their body weight. …